|
1
|
Zhu S, Soutto M, Chen Z, Peng D,
Romero-Gallo J, Krishna US, Belkhiri A, Washington MK, Peek R and
El-Rifai W: Helicobacter pylori-induced cell death is counteracted
by NF-κB-mediated transcription of DARPP-32. Gut. 66:761–762. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Power DG, Kelsen DP and Shah MA: Advanced
gastric cancer-slow but steady progress. Cancer Treat Rev.
36:384–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park HR, Tomida A, Sato S, Tsukumo Y, Yun
J, Yamori T, Hayakawa Y, Tsuruo T and Shin-ya K: Effect on tumor
cells of blocking survival response to glucose deprivation. J Natl
Cancer Inst. 96:1300–1310. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li XJ and Zhang HY: Western healers in
traditional Chinese medicine. EMBO Rep. 9:112–113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmidt BM, Ribnicky DM, Lipsky PE and
Raskin I: Revisiting the ancient concept of botanical therapeutics.
Nat Chem Biol. 3:360–366. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao J, Jiang P and Zhang W: Molecular
networks for the study of TCM pharmacology. Brief Bioinform.
11:417–430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meng Z, Garrett CR, Shen Y, Liu L, Yang P,
Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ and Cohen L: Prospective
randomised evaluation of traditional Chinese medicine combined with
chemotherapy: A randomised phase II study of wild toad extract plus
gemcitabine in patients with advanced pancreatic adenocarcinomas.
Br J Cancer. 107:411–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y, Jin F, Higgins R and Mcknight K:
The current view for the silencing of the spindle assembly
checkpoint. Cell Cycle. 13:1694–1701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang XB, Song L, Wen HJ, Bai XX, Li ZJ
and Ma LJ: Upregulation of microRNA-31 targeting integrin α5
suppresses tumor cell invasion and metastasis by indirectly
regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
Tumour Biol. 37:8317–8325. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Franke TF, Kaplan DR and Cantley LC: PI3K:
Downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Franke TF, Yang SI, Chan TO, Datta K,
Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein
kinase encoded by the Akt proto-oncogene is a target of the
PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:727–736.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okuzumi T, Fiedler D, Zhang C, Gray DC,
Aizenstein B, Hoffman R and Shokat KM: Inhibitor hijacking of Akt
activation. Nat Chem Biol. 5:484–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pugazhenthi S, Nesterova A, Sable C,
Heidenreich KA, Boxer LM, Heasley LE and Reusch JE: Akt/protein
kinase B up-regulates Bcl-2 expression through cAMP-response
element-binding protein. J Biol Chem. 275:10761–10766. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qian J, Zou Y, Rahman JS, Lu B and Massion
PP: Synergy between phosphatidylinositol 3-kinase/Akt pathway and
Bcl-xL in the control of apoptosis in adenocarcinoma cells of the
lung. Mol Cancer Ther. 8:101–109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu CY, Shiau CW, Kuo HY, Huang HP, Chen
MH, Tzeng CH and Chen KF: Cancerous inhibitor of protein
phosphatase 2A determines bortezomib-induced apoptosis in leukemia
cells. Haematologica. 98:729–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY
and Cheng AL: Down-regulation of phospho-Akt is a major molecular
determinant of bortezomib-induced apoptosis in hepatocellular
carcinoma cells. Cancer Res. 68:6698–6707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ling TJ, Xia T, Wan XC, Li DX and Wei XY:
Cerebrosides from the roots of Serratula chinensis.
Molecules. 11:677–683. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ling TJ, Ping WU, Liu MF and Wei XY:
Ceramides from the roots of Serratula chinensis. J Trop
Subtrop Botany. 13:403–407. 2005.
|
|
21
|
Abdel Hadi L, Di Vito C, Marfia G,
Ferraretto A, Tringali C, Viani P and Riboni L: Sphingosine kinase
2 and ceramide transport as key targets of the natural flavonoid
luteolin to induce apoptosis in colon cancer cells. PloS One.
10:e01433842015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Zhu Z, Fei SJ, Liu L, Sun M and
Zhang Q: Ceramide promoting apoptosis of SGC7901 cell. Cancer Res
Prev Treat. 991–994. 2011.
|
|
23
|
Zhang L, Cai Q, Lin J, Fang Y, Zhan Y,
Shen A, Wei L, Wang L and Peng J: Chloroform fraction of
Scutellaria barbata D. Don promotes apoptosis and suppresses
proliferation in human colon cancer cells. Mol Med Rep. 9:701–706.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Petrelli A and Giordano S: From single- to
multi-target drugs in cancer therapy: When aspecificity becomes an
advantage. Curr Med Chem. 15:422–432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gagliostro V, Casas J, Caretti A, Abad JL,
Tagliavacca L, Ghidoni R, Fabrias G and Signorelli P:
Dihydroceramide delays cell cycle G1/S transition via activation of
ER stress and induction of autophagy. Int J Biochem Cell Biol.
44:2135–2143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Feng Y, Wang N, Cheung F, Tan HY,
Zhong S, Li C and Kobayashi S: Chinese medicines induce cell death:
The molecular and cellular mechanisms for cancer therapy. Biomed
Res Int. 2014:5303422014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li-Weber M: Targeting apoptosis pathways
in cancer by Chinese medicine. Cancer Lett. 332:304–312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Muntean AG, Pang L, Poncz M, Dowdy SF,
Blobel GA and Crispino JD: Cyclin D-Cdk4 is regulated by GATA-1 and
required for megakaryocyte growth and polyploidization. Blood.
109:5199–5207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nigg EA: Cyclin-dependent protein kinases:
Key regulators of the eukaryotic cell cycle. Bioessays. 17:471–480.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Orlando DA, Lin CY, Bernard A, Wang JY,
Socolar JE, Iversen ES, Hartemink AJ and Haase SB: Global control
of cell-cycle transcription by coupled CDK and network oscillators.
Nature. 453:944–947. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression
patterns of PI3K/AKT/mTOR signaling pathway components in
colorectal cancer. J Am Coll Surg. 210:767–778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Umemura S, Yoshida S, Ohta Y, Naito K,
Osamura RY and Tokuda Y: Increased phosphorylation of Akt in
triple-negative breast cancers. Cancer Sci. 98:1889–1892. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu G, Song Y, Cui L, Wen Z and Lu X:
Inositol hexaphosphate suppresses growth and induces apoptosis in
HT-29 colorectal cancer cells in culture: PI3K/Akt pathway as a
potential target. Int J Clin Exp Pathol. 8:1402–1410.
2015.PubMed/NCBI
|
|
37
|
Badinloo M and Esmaeili-Mahani S:
Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the
cytotoxic effects of doxorubicin, vincristine, and etoposide in a
panel of cancer cell lines. Fundam Clin Pharmacol. 28:414–422.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang ZP, Zhao Y, Huang F, Chen J, Yao YH,
Li J and Wu XN: Equol inhibits proliferation of human gastric
carcinoma cells via modulating Akt pathway. World J Gastroenterol.
21:10385–10399. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu D, Tao J, Xu B, Qing W, Li P, Lu Q and
Zhang W: Phosphatidylinositol 3-kinase inhibitor LY294002
suppresses proliferation and sensitizes doxorubicin chemotherapy in
bladder cancer cells. Urol Int. 86:346–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xia LJ, Wu YL and Zhang FC: Combination of
cecropinXJ and LY294002 induces synergistic cytotoxicity, and
apoptosis in human gastric cancer cells via inhibition of the
PI3K/Akt signaling pathway. Oncol Lett. 14:7522–7528.
2017.PubMed/NCBI
|
